Advertisement

Topics

Celgene turns focus to solid tumors in I/O expansion

03:27 EDT 31 Jul 2017 | BioPharmaDive

Executives highlighted the potential to pursue combinations of Celgene's recently acquired PD-1 inhibitor with other approaches, including in the red-hot PARP inhibitor space.

Original Article: Celgene turns focus to solid tumors in I/O expansion

NEXT ARTICLE

More From BioPortfolio on "Celgene turns focus to solid tumors in I/O expansion"

Quick Search
Advertisement